PL3663296T3 - Sposób wytwarzania związków użytecznych w leczeniu rdzeniowego zaniku mięśni - Google Patents

Sposób wytwarzania związków użytecznych w leczeniu rdzeniowego zaniku mięśni

Info

Publication number
PL3663296T3
PL3663296T3 PL19200058.6T PL19200058T PL3663296T3 PL 3663296 T3 PL3663296 T3 PL 3663296T3 PL 19200058 T PL19200058 T PL 19200058T PL 3663296 T3 PL3663296 T3 PL 3663296T3
Authority
PL
Poland
Prior art keywords
preparation
treatment
compounds useful
muscular atrophy
spinal muscular
Prior art date
Application number
PL19200058.6T
Other languages
English (en)
Inventor
Hasane Ratni
Luke Green
Nikolai A. Naryshkin
Marla L. Weetall
Original Assignee
F. Hoffmann-La Roche Ag
Ptc Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53175048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3663296(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag, Ptc Therapeutics, Inc. filed Critical F. Hoffmann-La Roche Ag
Publication of PL3663296T3 publication Critical patent/PL3663296T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL19200058.6T 2014-05-15 2015-05-11 Sposób wytwarzania związków użytecznych w leczeniu rdzeniowego zaniku mięśni PL3663296T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461993839P 2014-05-15 2014-05-15

Publications (1)

Publication Number Publication Date
PL3663296T3 true PL3663296T3 (pl) 2023-08-07

Family

ID=53175048

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15721701T PL3143025T3 (pl) 2014-05-15 2015-05-11 Związki do leczenia rdzeniowego zaniku mięśni
PL19200058.6T PL3663296T3 (pl) 2014-05-15 2015-05-11 Sposób wytwarzania związków użytecznych w leczeniu rdzeniowego zaniku mięśni

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL15721701T PL3143025T3 (pl) 2014-05-15 2015-05-11 Związki do leczenia rdzeniowego zaniku mięśni

Country Status (36)

Country Link
US (1) US9969754B2 (pl)
EP (3) EP3143025B1 (pl)
JP (1) JP6236173B2 (pl)
KR (2) KR102256013B1 (pl)
CN (1) CN106459092B (pl)
AR (2) AR100442A1 (pl)
AU (1) AU2015261046C1 (pl)
BR (1) BR112016026205B1 (pl)
CA (1) CA2948561C (pl)
CL (1) CL2016002836A1 (pl)
CR (1) CR20160518A (pl)
DK (1) DK3143025T3 (pl)
EA (2) EA202090486A3 (pl)
ES (2) ES2761423T3 (pl)
FR (1) FR21C1039I2 (pl)
HR (2) HRP20192159T1 (pl)
HU (2) HUE046491T2 (pl)
IL (2) IL248653B (pl)
LT (1) LTC3143025I2 (pl)
MA (2) MA51988A (pl)
MX (1) MX371050B (pl)
MY (1) MY174284A (pl)
NL (1) NL301128I2 (pl)
NO (2) NO2021035I1 (pl)
NZ (1) NZ725008A (pl)
PE (1) PE20170128A1 (pl)
PH (1) PH12016502081B1 (pl)
PL (2) PL3143025T3 (pl)
PT (1) PT3143025T (pl)
RS (1) RS59718B1 (pl)
SG (1) SG11201609497TA (pl)
SI (2) SI3663296T1 (pl)
TW (1) TWI667239B (pl)
UA (1) UA119670C2 (pl)
WO (1) WO2015173181A1 (pl)
ZA (1) ZA201607026B (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3406252B1 (en) 2012-02-10 2020-05-13 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
CA2915764A1 (en) 2013-08-19 2015-02-26 F. Hoffmann-La Roche Ag Screening method
US10882868B2 (en) * 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
EP3298017B1 (en) 2015-05-20 2019-08-14 H. Hoffnabb-La Roche Ag Compounds for treating spinal muscular atrophy
EP3310169B1 (en) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Methods for modulating rna splicing
AU2016353961B2 (en) 2015-11-12 2019-08-29 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy
AR106652A1 (es) * 2015-11-12 2018-02-07 Hoffmann La Roche Compuestos para tratar la esclerosis lateral amiotrófica
CA3119019C (en) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
EP3386978B1 (en) 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Bridged piperidine derivatives
JP2019535789A (ja) * 2016-11-28 2019-12-12 ピーティーシー セラピューティクス，インコーポレーテッド Ｒｎａスプライシングを調節する方法
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
CN111372611A (zh) 2017-06-14 2020-07-03 Ptc医疗公司 修饰rna剪接的方法
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
HRP20251594T1 (hr) * 2017-09-22 2026-01-30 F. Hoffmann - La Roche Ag Postupak priprave derivata 7-(4,7-diazaspiro[2.5]oktan-7-il)-2-(2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4-ona
ES3072590T3 (en) * 2017-10-03 2026-07-02 Hoffmann La Roche New treatment of sma
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
WO2020004594A1 (ja) 2018-06-27 2020-01-02 株式会社リボルナバイオサイエンス 脊髄性筋萎縮症の予防または治療剤
CN120554386A (zh) * 2018-10-19 2025-08-29 豪夫迈·罗氏有限公司 新型吡啶并[1,2-a]嘧啶-4-酮衍生物、其制剂及制备方法
CA3139821A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2020249577A1 (en) 2019-06-12 2020-12-17 F. Hoffmann-La Roche Ag New treatment of sma
US12492214B2 (en) 2019-07-31 2025-12-09 Assia Chemical Industries Ltd. Solid state forms of Risdiplam and process for preparation thereof
MX2022012677A (es) * 2020-04-08 2023-01-11 Remix Therapeutics Inc Compuestos y metodos para modular el empalme.
WO2022048675A1 (zh) * 2020-09-07 2022-03-10 苏州科睿思制药有限公司 Risdiplam晶型及其制备方法和用途
WO2022162107A1 (en) 2021-02-01 2022-08-04 Sandoz Ag Crystalline form of risdiplam
EP4308577B1 (en) * 2021-03-17 2024-12-25 F. Hoffmann-La Roche AG New thiadiazolopyrimidone derivatives
EP4308572B1 (en) * 2021-03-17 2025-04-23 F. Hoffmann-La Roche AG New thienopyrimidinone derivatives
CR20230437A (es) 2021-03-17 2023-10-16 Hoffmann La Roche Nuevos derivados de tiazolopirimidinona
KR102973992B1 (ko) * 2021-03-18 2026-06-08 에프. 호프만-라 로슈 아게 리스디플람의 제조 방법
EP4426306A1 (en) 2021-10-06 2024-09-11 F. Hoffmann-La Roche AG Novel combined administration
CN118005654A (zh) * 2022-04-18 2024-05-10 深圳市塔吉瑞生物医药有限公司 取代的吡啶并嘧啶酮类化合物及包含该化合物的组合物及其用途
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
US20260098048A1 (en) * 2022-09-26 2026-04-09 Natco Pharma Limited Improved process for the preparation of risdiplam and its intermediates
JP2025534681A (ja) 2022-10-14 2025-10-17 ジェネンテック， インコーポレイテッド 脊髄性筋萎縮症の治療方法
EP4669647A1 (en) * 2023-01-21 2025-12-31 Harman Finochem Limited METHOD FOR PREPARING RISDIPLATIN, NEW INTERMEDIARIES AND THEIR METHOD FOR PREPARATION
WO2024218207A1 (en) 2023-04-20 2024-10-24 F. Hoffmann-La Roche Ag Thieno[3,2-b]pyridine derivatives
AU2024286618A1 (en) 2023-06-09 2025-10-30 F. Hoffmann-La Roche Ag Inducible gene expression system
CN117050096A (zh) * 2023-07-17 2023-11-14 杭州诺澳生物医药科技有限公司 一种利司扑兰的制备方法
AU2024365291A1 (en) 2023-10-27 2026-02-19 F. Hoffmann-La Roche Ag New composition for treating spinal muscular atrophy
WO2026125303A1 (en) 2024-12-11 2026-06-18 F. Hoffmann-La Roche Ag Inducible gene expression system

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0920429T3 (da) * 1996-08-06 2003-05-12 Pfizer Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater
CA2700841A1 (en) 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
US8633019B2 (en) * 2008-05-27 2014-01-21 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
KR20100012134A (ko) * 2008-07-28 2010-02-08 신호열 마우스
WO2010019236A1 (en) 2008-08-13 2010-02-18 Ptc Therapeutics, Inc Methods for treating spinal muscular atrophy
JP2011529722A (ja) * 2008-08-14 2011-12-15 カーディアック ペースメイカーズ， インコーポレイテッド 音響通信リンクの性能評価および適合
MX352861B (es) * 2011-12-30 2017-12-13 Ptc Therapeutics Inc Compuestos para tratar la atrofia muscular espinal.
MX357834B (es) * 2012-01-26 2018-07-26 Ptc Therapeutics Inc Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal.
EP3406252B1 (en) * 2012-02-10 2020-05-13 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
US9212209B2 (en) 2012-07-13 2015-12-15 Indiana University Research And Technology Corporation Screening methods for spinal muscular atrophy
AU2016353961B2 (en) 2015-11-12 2019-08-29 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy

Also Published As

Publication number Publication date
MA39995B1 (fr) 2019-11-29
EA035068B1 (ru) 2020-04-23
SI3663296T1 (sl) 2023-08-31
TW201609738A (zh) 2016-03-16
FR21C1039I1 (pl) 2021-10-15
US20170197990A1 (en) 2017-07-13
IL270027B (en) 2020-08-31
EP3663296A1 (en) 2020-06-10
KR102213740B1 (ko) 2021-02-09
BR112016026205A8 (pt) 2021-07-20
PT3143025T (pt) 2019-12-03
ES2761423T3 (es) 2020-05-19
JP6236173B2 (ja) 2017-11-22
CA2948561C (en) 2019-10-22
MA51988A (fr) 2021-01-20
DK3143025T3 (da) 2019-12-09
NO2021035I1 (no) 2021-09-10
UA119670C2 (uk) 2019-07-25
HRP20230637T1 (hr) 2023-09-29
MX2016014547A (es) 2017-02-23
KR20210014219A (ko) 2021-02-08
IL248653B (en) 2019-11-28
FR21C1039I2 (fr) 2022-09-02
SG11201609497TA (en) 2016-12-29
AU2015261046B2 (en) 2019-04-18
EA202090486A2 (ru) 2020-06-30
HRP20192159T1 (hr) 2020-02-21
EP3663296B1 (en) 2023-05-17
JP2017515863A (ja) 2017-06-15
BR112016026205B1 (pt) 2021-12-07
CN106459092B (zh) 2019-10-15
IL248653A0 (en) 2017-01-31
CL2016002836A1 (es) 2017-04-21
EP4241772A3 (en) 2023-11-15
EA202090486A3 (ru) 2020-08-31
PH12016502081A1 (en) 2017-01-09
PE20170128A1 (es) 2017-03-16
AU2015261046A1 (en) 2016-10-27
RS59718B1 (sr) 2020-01-31
TWI667239B (zh) 2019-08-01
KR102256013B1 (ko) 2021-05-26
EP4241772A2 (en) 2023-09-13
NL301128I1 (pl) 2021-09-22
NO2025038I1 (no) 2025-08-14
CR20160518A (es) 2017-02-21
AU2015261046C1 (en) 2019-07-25
US9969754B2 (en) 2018-05-15
KR20170003687A (ko) 2017-01-09
WO2015173181A1 (en) 2015-11-19
LTC3143025I2 (pl) 2023-11-10
NL301128I2 (nl) 2021-10-25
PH12016502081B1 (en) 2022-11-23
MY174284A (en) 2020-04-01
EP3143025B1 (en) 2019-10-09
CA2948561A1 (en) 2015-11-19
BR112016026205A2 (pt) 2017-08-15
PL3143025T3 (pl) 2020-03-31
HUS2100037I1 (hu) 2021-10-28
AR131260A2 (es) 2025-03-05
ES2949660T3 (es) 2023-10-02
MX371050B (es) 2020-01-14
ZA201607026B (en) 2022-05-25
CN106459092A (zh) 2017-02-22
AR100442A1 (es) 2016-10-05
LTPA2021010I1 (pl) 2021-10-11
SI3143025T1 (sl) 2020-01-31
NZ725008A (en) 2019-11-29
EA201692280A1 (ru) 2018-07-31
HUE046491T2 (hu) 2020-03-30
EP3143025A1 (en) 2017-03-22

Similar Documents

Publication Publication Date Title
HUS2100037I1 (hu) Vegyületek gerinc eredetû izomsorvadás kezelésére
IL279627A (en) A method for treating depression
IL253945B (en) kdm1a inhibitors to treat the disease
EP3373972C0 (en) COMPOSITIONS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY
PL3262071T3 (pl) Sposób stosowania immunokoniugatów anty-CD79b
EP3133919A4 (en) Agents and methods for treatment of pathogens
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
GB201410116D0 (en) Method of treatment
IL256985A (en) Compounds for inducing tissue formation and their uses
IL256980B1 (en) Compounds for inducing tissue formation and their uses
IL253028A0 (en) treatment method
PL3283064T3 (pl) Pochodne do zastosowania w atrofii mięśni
PL2937084T3 (pl) Sposób leczenia hipercholesterolemii
ZA201607027B (en) Method for treating or enhancing muscle tissue
IL286670A (en) Compounds for inducing tissue formation and their uses
IL256968A (en) Compounds for inducing tissue formation and uses thereof
EP3215154A4 (en) Salts and compositions useful for treating disease
GB201521083D0 (en) Compositions for treatment and methods thereof
GB201418268D0 (en) Composition & methods of treatment
GB201418272D0 (en) Composition & methods of treatment
GB201421980D0 (en) Method of treatment
GB201421982D0 (en) Method of treatment
GB201415331D0 (en) Method of treatment
GB201414780D0 (en) Method Of Treatment
AU2014901470A0 (en) Agents and methods for treatment of pathogens